Skip to content

Study · Randomized controlled trial · n = 10 · 1995

4 results

Treatment of pain in chronic pancreatitis by inhibition of pancreatic secretion with octreotide.

Malfertheiner P, Mayer D, Büchler M, Domínguez-Muñoz JE, Schiefer B, Ditschuneit H

Gut1 Mar 1995Cited by 55 (Europe PMC)

PMID7698708 (opens in a new tab)PMCIDPMC1382464 (opens in a new tab)DOI10.1136/gut.36.3.450 (opens in a new tab)PepBankPUB-07698708
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In chronic alcoholic pancreatitis, octreotide reduced faecal chymotrypsin to 1.7 (0.6) U/g versus 9.6 (4.2) U/g with placebo (p < 0.001).

    In plain wordsIn patients with chronic alcoholic pancreatitis, octreotide reduced pancreatic secretion versus placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseFaecal chymotrypsin versus placebo
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    3 x 100 micrograms/day · subcutaneous · three daysAs given in this study (human).

    Measurements

    Faecal chymotrypsin
    1.7 U/g
    octreotide period
    SD of faecal chymotrypsin
    0.6 U/g
    octreotide period
    Faecal chymotrypsin
    9.6 U/g
    placebo period
    SD of faecal chymotrypsin
    4.2 U/g
    placebo period
    P value
    < 0.001
    octreotide versus placebo and washout

    Source sentences

    Summary
    It was found that during the administration of octreotide, pancreatic secretion was strongly inhibited (faecal chymotrypsin mean (SD) 1.7 (0.6) U/g) with respect to placebo (9.6 (4.2) U/g) and washout (7.6 (3.1) U/g) periods (p < 0.001).
    2 context sentences
    Summary · context
    Ten patients with chronic alcoholic pancreatitis and severe daily pain were included in an intraindividual double blind crossover study.
    Summary · context
    All patients received octreotide (3 x 100 micrograms/day subcutaneously) and placebo (3 x 0.9% saline solution subcutaneously) for three days at random.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In chronic alcoholic pancreatitis, pain scores did not differ between octreotide and placebo periods: 29.6 (4.5) versus 28.7 (5.8).

    In plain wordsIn patients with chronic alcoholic pancreatitis, pain scores did not differ between octreotide and placebo periods.

    Peptide
    Octreotide
    Outcome
    No significant changePain score
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Pain · Gastrointestinal
    Studied dose
    3 x 100 micrograms/day · subcutaneous · three daysAs given in this study (human).

    Measurements

    Pain score (visual analogue scale)
    29.6
    octreotide period
    SD of pain score
    4.5
    octreotide period
    Pain score (visual analogue scale)
    28.7
    placebo period
    SD of pain score
    5.8
    placebo period

    Source sentences

    Summary
    Pain score (29.6 (4.5) v 28.7 (5.8)) and consumption of analgesics were no different during the octreotide and placebo periods.
    2 context sentences
    Summary · context
    Ten patients with chronic alcoholic pancreatitis and severe daily pain were included in an intraindividual double blind crossover study.
    Summary · context
    All patients received octreotide (3 x 100 micrograms/day subcutaneously) and placebo (3 x 0.9% saline solution subcutaneously) for three days at random.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In chronic alcoholic pancreatitis, analgesic consumption did not differ between octreotide and placebo periods.

    In plain wordsIn patients with chronic alcoholic pancreatitis, analgesic use did not differ between octreotide and placebo periods.

    Peptide
    Octreotide
    Outcome
    No significant changeAnalgesic consumption
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Pain · Gastrointestinal
    Studied dose
    3 x 100 micrograms/day · subcutaneous · three daysAs given in this study (human).

    Source sentences

    Summary
    Pain score (29.6 (4.5) v 28.7 (5.8)) and consumption of analgesics were no different during the octreotide and placebo periods.
    2 context sentences
    Summary · context
    Ten patients with chronic alcoholic pancreatitis and severe daily pain were included in an intraindividual double blind crossover study.
    Summary · context
    All patients received octreotide (3 x 100 micrograms/day subcutaneously) and placebo (3 x 0.9% saline solution subcutaneously) for three days at random.
  4. 04HumanNon-randomized trialEfficacy outcome

    In chronic alcoholic pancreatitis, faecal chymotrypsin was 1.7 (0.6) U/g during octreotide versus 7.6 (3.1) U/g during washout (p < 0.001).

    In plain wordsIn patients with chronic alcoholic pancreatitis, pancreatic secretion was lower during octreotide than during washout.

    Peptide
    Octreotide
    Outcome
    DecreaseFaecal chymotrypsin versus washout
    Study

    n = 10

    Comparator
    Washout period
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    3 x 100 micrograms/day · subcutaneous · three daysAs given in this study (human).

    Measurements

    Faecal chymotrypsin
    1.7 U/g
    octreotide period
    SD of faecal chymotrypsin
    0.6 U/g
    octreotide period
    Faecal chymotrypsin
    7.6 U/g
    washout period
    SD of faecal chymotrypsin
    3.1 U/g
    washout period
    P value
    < 0.001
    octreotide versus placebo and washout

    Source sentences

    Summary
    It was found that during the administration of octreotide, pancreatic secretion was strongly inhibited (faecal chymotrypsin mean (SD) 1.7 (0.6) U/g) with respect to placebo (9.6 (4.2) U/g) and washout (7.6 (3.1) U/g) periods (p < 0.001).
    2 context sentences
    Summary · context
    Ten patients with chronic alcoholic pancreatitis and severe daily pain were included in an intraindividual double blind crossover study.
    Summary · context
    All patients received octreotide (3 x 100 micrograms/day subcutaneously) and placebo (3 x 0.9% saline solution subcutaneously) for three days at random.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.